Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application
Veristat partnered with Clene Nanomedicine to reduce the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%, from up to six weeks to one week.
Why it matters — The report describes a faster process for preparing validated tables, listings and figures for Clene’s ALS application submission.